The Asia-Pacific Continuous Bioprocessing Market is expected to grow at a CAGR of 28.9% from 2024 to 2030 to reach $181.1 million by 2030. Continuous manufacturing is an emerging trend spanning various industries. From automotive to paper, businesses are embracing continuous manufacturing to enhance efficiency and bolster profits. The shift from batch to continuous manufacturing is gaining traction in the biopharmaceuticals sector due to the surge in demand for intricate therapies and heightened market competition. Continuous bioprocessing is increasingly being adopted due to its agility, flexibility, efficiency, and robustness. This approach streamlines processes by minimizing steps, utilizing compact facilities and equipment, and enhancing product quality to facilitate real-time release.
The growth of the continuous bioprocessing market in Asia-Pacific is attributed to the gradual adoption of continuous manufacturing, rising manufacturing and research-related outsourcing of biopharmaceuticals, expansions in CDMOs, and initiatives supporting the adoption of biopharmaceuticals. Furthermore, the shift towards bioprocessing 4.0 and the rising adoption of personalized medicines are expected to provide significant market growth opportunities.
However, the limitations of continuous bioprocessing may restrain the growth of this market. Additionally, manufacturers’ hesitation to shift from batch manufacturing to continuous manufacturing poses challenges to the market players.
Click here to: Get Free Sample Pages of this Report
Companies Initiatives for Expanding Biopharma Capacity Drive Asia-Pacific Continuous Bioprocessing Market
The current push of biotech R&D towards establishing a biotherapeutic landscape and improving the regulatory landscape for the development and approval of biosimilars supported companies to expand biopharma capacity:
-
In December 2020, Alvotech (Iceland) and Fuji Pharma, a Japanese pharmaceutical company, extended their partnership to commercialize four biosimilars in Japan.
- In December 2020, RoosterBio, Inc., a South Korean supplier of cellular therapy bioprocess tools, entered into an agreement with Sartorius Korea Biotechto launch RoosterBio’s first international platform with off-the-shelf working cell banks and hMSC bioprocess media products in Asia.
- In October 2020, the company announced raising funding from private equity investors for investments in biologics. In January 2021, Biocon announced an investment of USD 75 million for Biocon Biologics to boost biosimilar development in India.
- Companies like Biocon Ltd. (India) are developing strategies to expand their R&D base in India. In September 2019, Biocon acquired Pfizer Healthcare (U.S.) assets to set up a second R&D facility in India to boost biosimilars development.
- In June 2018, Lupin Limited (India) partnered with Nichi-Iko Pharmaceutical Co., Ltd., to launch biosimilars in the Japanese market.
Support Initiatives for CDMOs Boosts R&D Development in the Asia-Pacific Continuous Bioprocessing Market
The demand for innovative manufacturing methods like continuous processing is rising due to the increasing R&D and bioproduction. For instance,
- In January 2021, Biocon announced an investment of USD 75 million for Biocon Biologics to boost biosimilar development in India.
- In November 2020, South Korea-based Celltrion announced an investment of USD 453 million for building a third manufacturing and R&D site in South Korea.
- In August 2020, one of the leading CDMOs in Japan, Bushu Pharmaceuticals Ltd., announced a major expansion program with an investment of USD 100 million to expand capacity and portfolio.
Key Findings in the Asia-Pacific Continuous Bioprocessing Market Study:
In 2024, the Filtration Systems and Consumables Segment is Expected to Account for the Largest Share of the Asia-Pacific Continuous Bioprocessing Market
In 2024, the filtration systems and consumables segment is estimated to account for the largest share of the Asia-Pacific continuous bioprocessing market. Filtration stands as a preferred purification method in the biopharmaceutical sector. The surge in advanced filtration systems and consumables, such as disposable or single-use systems, combined with the filters' reusability across various bioprocessing steps, contributes to the significant market share of this segment.
In 2024, the Commercial Application Segment is Expected to Account for the Largest Share of the Asia-Pacific Continuous Bioprocessing Market
In 2024, the commercial applications segment is estimated to account for the largest share of the Asia-Pacific continuous bioprocessing market. Growing initiatives supporting the adoption of biopharmaceuticals, rising biopharmaceutical manufacturing outsourcing, growing investments in constructing facilities compatible with continuous bioprocessing for the commercial manufacture of biopharmaceuticals, and accelerated developments in personalized therapies drive the adoption of continuous bioprocessing for commercial application.
In 2024, the Pharmaceutical and Biotechnology Companies Segment is Expected to Account for the Largest Share of Asia-Pacific Continuous Bioprocessing Market
In 2024, the pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the Asia-Pacific continuous bioprocessing market. The large share of this segment is attributed to factors such as the transition of pharma and biopharma manufacturers from batch to continuous processing, regulatory authorities' increasing emphasis on continuous bioprocessing, and the rising investments directed toward the integration of continuous processing technologies.
China to Account for the Largest Market Share in 2024
In 2024, China is estimated to dominate the Asia-Pacific continuous bioprocessing market. Though China has the largest adoption, China’s biopharma sector faces multiple challenges in quality management, including a lack of experience and talent, a rapidly changing regulatory environment, as well as cultural issues in management. These factors are projected to hinder the growth of this market to a certain extent.
Key Players
The report includes a competitive landscape based on the key growth strategies adopted by leading market players in the past four years. The key players profiled in Asia-Pacific continuous bioprocessing market study are 3M Company (U.S.), Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), Solida Biotech GmBH (Germany), Electrolab Biotech Limited (U.K.), Biowest (France), and Bionet (U.S.).
Scope of the Report:
Asia-Pacific Continuous Bioprocessing Market Assessment, by Product
- Filtration Systems and Consumables
- Chromatography Systems and Consumables
- Cell Culture Media, Buffers, and Reagents
- Incubators and Shakers
- Bioreactors
- Centrifuges
- Sterilizers
- Other Instruments and Consumables
Asia-Pacific Continuous Bioprocessing Market Assessment, by Application
- Commercial Applications
- Monoclonal Antibodies (MAB) Production
- Cell and Gene Therapy Production
- Vaccine Manufacturing
- Plasma Fractionation
- Recombinant Protein Production
- Research & Development (R&D)
Asia-Pacific Continuous Bioprocessing Market Assessment, by End User
- Pharmaceutical and Biotechnology Companies
- Contract Development and Manufacturing Organizations (CDMOS) and Contract Research Organizations (CROS)
- Academic and Research Institutes
Asia-Pacific Continuous Bioprocessing Market Assessment, by Country
- China
- India
- Japan
- Singapore
- South Korea
- Australia
- New Zealand
- Indonesia
- Rest of Asia-Pacific (RoE)
Key questions answered in the report:
